Merry Christmas and a happy new year!
A review of the year – Is the industry really already in post-COVID mode? What role does the new MDR play and, more generally, what impact do growing regulatory requirements have? Has everything improved? What are the challenges of tomorrow?
Our contribution is to create security – for our customers!
We ensure that our products are in the right place at the right time and that they are used safely to benefit patients. Thank you for your trust!
A heartfelt thank you to all our customers and suppliers! We appreciate your trust in our long-standing partnerships, collaborative exchange, and professional cooperation.
The industry-outlook for 2025 was optimistic. For a long time, it was believed that the Covid period was over and that the year would be a year of growth. And in some areas, this may have happened. For us, 2025 turned into a year where we significantly develop our skills and enhance customer service.
Our products are best-in-class. We knew that already but had it validated in a study. Best-in-class means, for example, that our pipettes’ friction forces remain within ideal ISO norm ranges even after 100 cycles. The entire product range complies with current MDR standards — a rare achievement, ensuring customers can rely on us. Most importantly, patients experience optimal usability during their personally challenging times of illness — accuracy and user-friendliness are paramount.
Our Quality Team successfully supported pharma customers with approvals, material compliance, and usability studies, including the internal validuation of material to ensure the launch of our new Bio-Pipette. This product symbolizes our technical expertise at elmplastic. We can now produce plastic devices that demonstrate a net zero emissions footprint—Cradle to Gate, binding more CO₂ than they emit.
Our sustainability effort continues with eco-friendly packaging and emissions-free door-to-door transportation—Pharma Net Zero! We can do it — do you want to join us?
Additionally, we expanded our capabilities into pharma-compliant 3D printing. Pharma development is heading toward highly specialized drug development, and elmplastic offers tailored solutions from small batches to multimillion quantities —digital design, 3D printed or injection molded, conventional or sustainable, Documentation complinane, ensuring biocompatibility and cytotoxy testing, CE marking – matching local requirements of global customers.
It’s been an exciting year, opening new doors and strengthening our own and our customers market position. Thank you for your trust.
